Source: Eur Respir J 2014; 44: 789-791
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Bafadhel Mona, Davies Lisa, Calverley Peter M.A., Aaron Shawn D., Brightling Christopher E., Pavord Ian D.. Blood eosinophil guided prednisolone therapy for exacerbations of COPD: a further analysis. Eur Respir J 2014; 44: 789-791

Member's Comments

No comment yet.

Related content which might interest you: Blood eosinophil guided prednisolone therapy for exacerbations of COPD: A further analysis Source: International Congress 2014 – COPD exacerbations Year: 2014 Minimal effect of inhaled corticosteroids (ICS) on blood eosinophil count in steroid-naïve COPD patients Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis Year: 2015 Association between blood eosinophil count and exacerbation risk in patients with asthma receiving medium- or high-dosage inhaled corticosteroids Source: International Congress 2017 – Biomarker-based asthma control Year: 2017 Blood eosinophils as a marker of response to inhaled corticosteroids in COPD Source: Eur Respir J 2016; 47:1374-1382 Year: 2016 Failure of montelukast to reduce sputum eosinophilia in high-dose corticosteroid-dependent asthma Source: Eur Respir J 2005; 25: 41-46 Year: 2005 Use of Inhaled corticosteroid (ICS)-containing regimen for COPD patients with high or low blood eosinophilia: A meta-analysis Source: International Congress 2018 – Clinical determinants and biomarkers of COPD Year: 2018 LATE-BREAKING ABSTRACT: Blood eosinophils (EOS) are a biomarker of COPD exacerbation reduction with inhaled corticosteroids (ICS): An across-trials model-based approach Source: International Congress 2016 – New and old therapies for chronic lung diseases Year: 2016 Screening eosinophil counts and risk of exacerbations after inhaled corticosteroid withdrawal in severe COPD Source: International Congress 2016 – Novel avenues in the treatment of COPD II Year: 2016 Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatment Source: Eur Respir J 2006; 27: 964-971 Year: 2006 Effect of indacaterol/glycopyrronium (IND/GLY) vs salmeterol/fluticasone (SFC) on moderate or severe COPD exacerbations and lung function based on baseline blood eosinophil counts: Results from the FLAME study Source: International Congress 2016 – Pharmacological management of COPD Year: 2016 LATE-BREAKING ABSTRACT: Evaluating blood eosinophils and exacerbation history to predict ICS response in COPD Source: International Congress 2016 – Late-breaking topics in airways disease Year: 2016 Patients with COPD prescribed inhaled corticosteroid in primary care – Time for re-assessment based on exacerbation rate and blood eosinophils? Source: Virtual Congress 2020 – Diagnosis and management of airways disease in primary care Year: 2020 Pharmacodynamic effect of benralizumab on blood basophils and serum biomarkers in adults with COPD with sputum eosinophilia Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD Year: 2015 The impact of stepwise withdrawal of inhaled corticosteroids on exacerbations in COPD patients receiving dual bronchodilation: WISDOM study Source: International Congress 2014 – Bronchodilators for asthma and COPD Year: 2014 LATE-BREAKING ABSTRACT: Exacerbation phenotype directed corticosteroid therapy of COPD: Value of blood eosinophilia (primary results) Source: International Congress 2015 – The relevance of diagnostic and monitoring tools in clinical practice Year: 2015 Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations Source: Eur Respir J 2006; 27: 483-494 Year: 2006 Persistent blood eosinophilia and COPD exacerbation risk after ICS withdrawal from triple therapy in the SUNSET study Source: International Congress 2018 – Eosinophils in airway disease Year: 2018 Effect of COPD exacerbations on early lung function decline under maintenance therapy: blood eosinophil count asbiomarker Source: International Congress 2019 – Eosinophils and FeNO in airway diseases Year: 2019 Cost-effectiveness of single-inhaler triple therapy for chronic obstructive pulmonary disease treatment by baseline blood eosinophil count: IMPACT trial Source: Virtual Congress 2021 – Difficult decisions on expected outcomes: availability of hospital resources and improvement of treatment adherence Year: 2021 The impact of stepwise withdrawal of inhaled corticosteroids on lung function in COPD patients receiving dual bronchodilation: WISDOM study Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014